Nektar Therapeutics
NKTR
Delayed Nasdaq - 04/25 10:00:00 pm
82.59USD
-2.27%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 20172018
Sales308540
EBITDA-28,9337
Operating profit (EBIT)-43,757,2
Pre-Tax Profit (EBT)--
Net income-96,727,0
EPS ( $ )-0,620,00
Dividend per Share ( $ )--
Yield--
Announcement Date03/01/2018
09:40pm
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 20172018
Debt--
Finance50,9-
Operating income (EBITDA)-28,9337
Leverage
(Debt/EBITDA)
--
Capital Expenditure9,682,63
Book Value Per Share (BVPS)0,55 $7,74 $
Cash Flow per Share-0,52 $4,73 $
Announcement Date03/01/2018
09:40pm
-
Balance Sheet Analysis
Financial Ratios
Size 2018e 2019e
Capitalization 13 600 M$ -
Entreprise Value (EV) - 13 600 M$
Valuation 2018e 2019e
P/E ratio (Price / EPS) 82 590x
Capitalization / Revenue 25,2x 42,1x
EV / Revenue - -
EV / EBITDA - -
Yield (DPS / Price) - -
Price to book (Price / BVPS) 10,7x 75,4x
Profitability 2018e 2019e
Operating Margin (EBIT / Sales) 10,6% -53,6%
operating Leverage (Delta EBIT / Delta Sales) 3,06x -10,0x
Net Margin (Net Profit / Revenue) 4,99% -52,8%
ROA (Net Profit / Asset) 13,3% 7,00%
ROE (Net Profit / Equities) 40,0% 9,00%
Rate of Dividend - -
Balance Sheet Analysis 2018e 2019e
CAPEX / CA   0,49% 3,14%
Cash Flow / Sales 141% -
Capital Intensity (Assets / Sales) 0,38x -7,55x
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
BNA & Dividende